LIVE @ 11AM CT - The “Exercise Pill”
How could it change obesity treatment?
ON THE PEN
GLP-1 and obesity medicine news.
Live Last read · last published · next check
Latest posts
I Was Selling Traffic Signals. Then Everything Changed.
I’ve Never Told This Part of the On The Pen Story
EXCLUSIVE: Wegovy FlexTouch Is Coming to America
Here’s why this is a big deal….
LIVE NOW: Lilly Earnings Call Recap! Retatrutide News!
Watch now live, or ondemand later by clicking play below!
LIVE NOW: Meet The New Tirzepatide Add On From Lilly (not Eloralintide)
These are fun videos… The videos where we get to introduce you to new molecules that no one else on the web is talking about.
I Think Everyone Is Looking at the Retatrutide Lawsuit the Wrong Way
This matters to anyone watching the GLP-1 space closely
The SAFE Drugs Act No Longer a Threat to Compounded GLP-1
We spoke. Washington listened.
BREAKING: Lilly Just Put Retatrutide on the Road to Approval, and Three Letters Changed the Conversation
The latest in a 2 year long saga...
This Study Changes the GLP-1 Deficiency Debate
This may be one of the most important obesity papers published all year.
Boehringer’s Next Obesity Bet Not Just Another Incretin, It’s One of the Brain’s Most Powerful Hunger Pathways
Over the past few years, we’ve watched obesity medicines evolve from our favorite GLP-1 therapies we discuss like semaglutide, or dual agonists like tirzepatide, and now to triple agonists like retatrutide.